Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Public ClinicalTrials.gov record NCT02706392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
Study identification
- NCT ID
- NCT02706392
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Enrollment
- 21 participants
Conditions and interventions
Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Mantle Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
- Unresectable Lung Non-Small Cell Carcinoma
Interventions
- Laboratory Biomarker Analysis Other
- ROR1 CAR-specific Autologous T-Lymphocytes Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2016
- Primary completion
- May 16, 2021
- Completion
- Sep 27, 2021
- Last update posted
- Aug 30, 2022
2016 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02706392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2022 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02706392 live on ClinicalTrials.gov.